FDA Clears New Transplant Therapy

WashingtonFDA approved Orca Bio’s Tregzi therapy.

Tregzi engineers donor T cells to lower the risk of graft-versus-host disease, a complication that has long limited who can safely receive a transplant.

Orca Bio has not disclosed Tregzi’s price, leaving cost and access questions for blood cancer patients unanswered.

Sources: STAT